AG-181 is under clinical development by Agios Pharmaceuticals and currently in Phase I for Phenylketonuria (PKU). According to GlobalData, Phase I drugs for Phenylketonuria (PKU) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AG-181’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AG-181 overview
AG-181 is under development for the treatment of phenylketonuria (PKU). It acts by targeting phenylalanine hydrolase (PAH). It is administered through oral route.
Agios Pharmaceuticals overview
Agios Pharmaceuticals (Agios) discovers and develops investigational medicines for the treatment of cancer and rare genetic metabolic disorders. Its pipeline products include AG-946 a PKR activator that targets hemolytic anemias and sickle cell disease; AG-181 phenylalanine hydroxylase stabilizer that treats phenylketonuria (PKU); mitapivat treats adult pyruvate kinase (PK) deficiency, adult thalassemia, adult sickle cell disease, pediatric PK deficiency, pediatric thalassemia and pediatric sickle cell disease. Agios offers myAgios patient support services program that includes access support, prescription fulfillment, financial assistance, disease education and community connections. The company operates through its subsidiaries in Switzerland, the Netherlands, Germany, Italy and France, among others. Agios is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of AG-181’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
